Literature DB >> 1570811

Bone mineral status in children with phenylketonuria--relationship to nutritional intake and phenylalanine control.

M P McMurry1, G M Chan, C O Leonard, S L Ernst.   

Abstract

The mineral status in phenylketonuria (PKU) was measured by single-photon densitometry of the distal radius and plasma concentrations in 26 subjects. Bone mineral content increased normally with age in the younger children despite strict dietary restrictions. Subjects aged greater than 8 y, however, were frequently below the normal curve for bone mineral content. Blood phenylalanine concentrations were significantly higher in the older group of subjects and this correlated with decreased compliance with dietary prescriptions. PKU children had significantly decreased plasma concentrations of alkaline phosphatase, magnesium, and parathyroid hormone. Subnormal concentrations of plasma zinc and plasma and red blood cell (RBC) copper were common, but RBC zinc was normal. We conclude that compliance with dietary therapy for PKU is associated with normal bone mineral development in young children. Older patients with PKU who follow the diet less carefully are at risk for low bone mineral content.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1570811     DOI: 10.1093/ajcn/55.5.997

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN: 0002-9165            Impact factor:   7.045


  24 in total

1.  Bone development in children and adolescents with PKU.

Authors:  A B Mendes; F F Martins; W M S Cruz; L E da Silva; C B M Abadesso; G T Boaventura
Journal:  J Inherit Metab Dis       Date:  2011-11-11       Impact factor: 4.982

2.  A study of bone turnover markers in prepubertal children with phenylketonuria.

Authors:  Jadwiga Ambroszkiewicz; Joanna Gajewska; Teresa Laskowska-Klita
Journal:  Eur J Pediatr       Date:  2004-01-29       Impact factor: 3.183

3.  Treatment products and approaches for phenylketonuria: improved palatability and flexibility demonstrate safety, efficacy and acceptance in US clinical trials.

Authors:  A P Prince; M P McMurray; N R Buist
Journal:  J Inherit Metab Dis       Date:  1997-08       Impact factor: 4.982

4.  Elevated plasma phenylalanine concentrations may adversely affect bone status of phenylketonuric mice.

Authors:  S Yannicelli; D M Medeiros
Journal:  J Inherit Metab Dis       Date:  2002-09       Impact factor: 4.982

5.  Demographic and Psychosocial Influences on Treatment Adherence for Children and Adolescents with PKU: A Systematic Review.

Authors:  Emma Medford; Dougal Julian Hare; Anja Wittkowski
Journal:  JIMD Rep       Date:  2017-08-25

6.  Impact of Dietary Intake on Bone Turnover in Patients with Phenylalanine Hydroxylase Deficiency.

Authors:  Kathryn E Coakley; Eric I Felner; Vin Tangpricha; Peter W F Wilson; Rani H Singh
Journal:  JIMD Rep       Date:  2017-01-28

Review 7.  Phenylketonuria Pathophysiology: on the Role of Metabolic Alterations.

Authors:  Patrícia Fernanda Schuck; Fernanda Malgarin; José Henrique Cararo; Fabiola Cardoso; Emilio Luiz Streck; Gustavo Costa Ferreira
Journal:  Aging Dis       Date:  2015-10-01       Impact factor: 6.745

8.  Bone impairment in phenylketonuria is characterized by circulating osteoclast precursors and activated T cell increase.

Authors:  Ilaria Roato; Francesco Porta; Alessandro Mussa; Lucia D'Amico; Ludovica Fiore; Davide Garelli; Marco Spada; Riccardo Ferracini
Journal:  PLoS One       Date:  2010-11-30       Impact factor: 3.240

9.  Decreased bone mineralization in children with phenylketonuria under treatment.

Authors:  L Hillman; C Schlotzhauer; D Lee; J Grasela; S Witter; S Allen; R Hillman
Journal:  Eur J Pediatr       Date:  1996-07       Impact factor: 3.183

10.  Benefits of normalizing plasma phenylalanine: impact on behaviour and health. A case report.

Authors:  K Williams
Journal:  J Inherit Metab Dis       Date:  1998-12       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.